Investment Rating - The report assigns a "Buy" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with annual growth rates of 20.5%, 10.4%, 15.5%, 17.7%, and 17.6% respectively [4][11]. - Net profit attributable to the parent company is expected to fluctuate, with estimates of 159 million CNY in 2023, dropping to 110 million CNY in 2024, and then recovering to 205 million CNY by 2027 [4][11]. - Earnings per share (EPS) is projected to increase from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][11]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive significant revenue growth [17][27]. - The commercialized mouse model segment is the cornerstone of the business, with revenue growth supported by an increase in high-end product sales and operational efficiency improvements [22][27]. - The pharmacodynamic service segment is expected to become a key revenue growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company has seen significant growth in overseas revenue, reaching 1.07 billion CNY in the first three quarters of 2025, a year-on-year increase of 23.62% [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive further revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to future growth [33][34]. Profitability Forecast and Investment Recommendations - The company is projected to achieve revenues of 9.34 billion CNY and 10.99 billion CNY in 2026 and 2027, respectively, with corresponding net profits of 1.74 billion CNY and 2.05 billion CNY [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services, along with ongoing overseas expansion, will enhance profitability [10][42]. - A valuation based on comparable companies suggests a target price of 23.65 CNY, reflecting a 55 times PE ratio for 2026 [10][40][42].

Investment Rating - The report assigns an "Accumulate" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with a compound annual growth rate (CAGR) of 17.6% [4][39]. - Net profit attributable to the parent company is expected to increase from 159 million CNY in 2023 to 205 million CNY in 2027, with a significant growth of 31.5% in 2025 [4][42]. - Earnings per share (EPS) is forecasted to rise from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][42]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive revenue growth [17][27]. - The commercialized mouse model business is the cornerstone, with revenue growth supported by an increase in high-end product sales and improved gross margins [22][25]. - The pharmacodynamic service segment is expected to become a significant growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company reported overseas revenue of 1.07 billion CNY in the first three quarters of 2025, marking a year-on-year increase of 23.62%, with a notable 63.97% growth in Q3 [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive future revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to long-term growth potential [33][34]. Profitability Forecast and Investment Recommendations - Revenue is projected to grow steadily, with expectations of 9.34 billion CNY in 2026 and 10.99 billion CNY in 2027, maintaining a growth rate of 17.7% and 17.6% respectively [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services will enhance profitability over time [10][42]. - Based on comparable company valuations, a price-to-earnings (PE) ratio of 55 times for 2026 is recommended, leading to a target price of 23.65 CNY [10][40][42].